Derivatives of N-phenyl (piperidine-2-yl) methyl benzamide, preparation method thereof and applications of same in therapeutics

• US 7,750,025 B2
• Filed: 04/17/2006
• Issued: 07/06/2010
• Est. Priority Date: 10/17/2003
• Status: Expired due to Fees

• Current Assignee: Sanofi-Aventis (Sanofi )
• Original Assignee: Sanofi-Aventis (Sanofi )
• Inventors: Magat, Pascale, Dargazanli, Gihad, Estenne-Bouhtou, Genevieve
• Primary Examiner(s): CHANG, CELIA C
• Application Number:
  US11/405,169
• Publication Number:
  US 20060223885A1
• Time in Patent Office: 1,541 Days
• Field of Search: 514/241, 514/249, 514/256, 514/307, 514/311, 514/318, 514/321, 514/322, 514/324, 514/326, 546/113, 546/114, 546/115, 546/139, 546/152, 546/194, 546/198, 546/199, 546/201, 546/205, 546/209, 546/210, 546/211, 546/212, 546/214, 544/212, 544/288, 544/333, 544/349, 544/353
• US Class Current: 514/324
• CPC Class Codes: A61P 1/14 Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 25/06 Antimigraine agents
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/18 Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 25/30 for treating abuse or dependence
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 403/12 linked by a chain containing hetero atoms as chain links
• CPC Class Codes: C07D 409/12 linked by a chain containing hetero atoms as chain links

Abstract

Compounds of formula (I) as defined herein:

are useful for treating behavioral disorders associated with dementia, psychoses, in particular schizophrenia (deficient form and productive form) and acute or chronic extrapyramidal symptoms induced by neuroleptics; for the treatment of various forms of anxiety, panic attacks, phobias, and compulsive obsessive disorders; for treating various forms of depression, including psychotic depression; for treating disorders caused by alcohol abuse or weaning from alcohol, sexual behavior disorders, eating disorders and for treating migraine. Moreover, the compounds of the invention may be used for treating painful muscle contracture in rheumatology and in acute spinal pathology; for treating spastic contractures of medullary or cerebral origin; for the symptomatic treatment of acute and subacute pain of light to moderate intensity; for treating intense and/or chronic pain, neurogenic pain and intractable pain; for treating Parkinson'"'"'s disease and Parkinson-like symptoms of neurodegenerative origin or induced by neuroleptics; for treating partial primary and secondary generalized epilepsy of simple or complex symptomology, mixed forms and other epileptic syndromes in addition to another antiepileptic treatment, or in monotherapy, for the treatment of sleep apnea, and for neuroprotection.

Claims

1. A compound of formula (I)

2. A compound according to claim 1 selected from the group consisting of:

threo-2,5-dichloro-N-[(1-methyl-2-piperidyl)(phenyl)methyl]thiophene-3-carboxamide; and

2,5-dichloro-N-[(S)-[(2S)-1-methyl-2-piperidyl](phenyl)methyl]thiophene-3-carboxamide;

or an acid addition salt thereof.

3. A pharmaceutical composition which comprises a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, combined with an excipient.

4. A method for treating a behavioral disorder selected from the group consisting of schizophrenia, anxiety, and depression, which comprises administering to a patient with said disorder an effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.